Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Medulloblastoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7X-Rays 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Temozolomide 4Biopsy 4ulixertinib 2tipifarnib 2selpercatinib 2olaparib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Vincristine 2Cyclophosphamide 2Cisplatin 2tazemetostat 1pembrolizumab 1palbociclib 1lutetium Lu 177 dotatate 1Vemurafenib 1Vascular Endothelial Growth Factor A 1Triiodothyronine 1Thiotepa 1Radiotherapy 1Radiation 1Platinum 1Pharmacogenomic Variants 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Diphtheria-Tetanus Vaccine × 30 days × Clear all
NCT05096481 2026-05-11

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡